LY3493269 + sodium caprate

LY3493269 + sodium caprate is an oral combination drug in development for metabolic disorders, specifically type 2 diabetes mellitus. **LY3493269** is a small molecule dual agonist of the **glucose-dependent insulinotropic polypeptide receptor (GIP receptor)** and the **glucagon-like peptide-1 receptor (GLP-1 receptor)**, aiming to improve glucose control and reduce body weight and appetite. **Sodium caprate** (also known as SNAC) is a permeation enhancer intended to improve the oral absorption of LY3493269 by increasing gastrointestinal permeability. This combination is being developed to enable the oral delivery of a peptide otherwise given by injection, with the potential to improve adherence and convenience for patients[1][2]. Early clinical studies focus on safety, pharmacokinetics (PK), pharmacodynamics (PD), and tolerability in healthy participants by evaluating glucose, insulin, C-peptide, triglycerides, appetite, and body weight[1][2].

Other names

sodium capratesodium decanoatesodium caprinatedecanoic acid, sodium saltC10C-10C 10SNAC